Systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor-lysate vaccine inducing the rejection of a highly aggressive T-cell lymphoma
T-cell lymphomas include diverse malignancies. They are rare, some have low survival rates and they lack curative therapies. The aim of this work was to assess whether employing the TLR7 agonist imiquimod and the T-cell costimulatory molecule CD40 or the combination of both as adjuvants of a cell ly...
| Autores principales: | , , , , , |
|---|---|
| Formato: | info:ar-repo/semantics/artículo |
| Lenguaje: | Inglés |
| Publicado: |
Elsevier
2019
|
| Materias: | |
| Acceso en línea: | https://www.sciencedirect.com/science/article/pii/S1521661618304212 http://hdl.handle.net/20.500.12123/6229 https://doi.org/10.1016/j.clim.2019.04.013 |
| _version_ | 1855035638255976448 |
|---|---|
| author | Di Sciullo, Maria Paula Menay, Florencia Cocozza, Federico Gravisaco, María José Waldner, Claudia Inés Mongini, Claudia |
| author_browse | Cocozza, Federico Di Sciullo, Maria Paula Gravisaco, María José Menay, Florencia Mongini, Claudia Waldner, Claudia Inés |
| author_facet | Di Sciullo, Maria Paula Menay, Florencia Cocozza, Federico Gravisaco, María José Waldner, Claudia Inés Mongini, Claudia |
| author_sort | Di Sciullo, Maria Paula |
| collection | INTA Digital |
| description | T-cell lymphomas include diverse malignancies. They are rare, some have low survival rates and they lack curative therapies. The aim of this work was to assess whether employing the TLR7 agonist imiquimod and the T-cell costimulatory molecule CD40 or the combination of both as adjuvants of a cell lysate vaccine could enhance the antitumor immune response using a murine T-cell lymphoma model.
Immunization with LBC-lysate and imiquimod protected almost all vaccinated animals. A specific humoral and a Th1-type cellular immunity were induced in mice that rejected the lymphoma, characterized by an elevated number of CD4 + T-cells and secretion of IFN-γ, locally and systemically. In contrast, CD40 alone or in combination with imiquimod did not improve the protective response obtained with LBC-lysate and imiquimod. Systemic administration of imiquimod proved to have high potential to serve as a vaccine adjuvant for the treatment of T-cell lymphomas and was effective in this immunotherapy model. |
| format | info:ar-repo/semantics/artículo |
| id | INTA6229 |
| institution | Instituto Nacional de Tecnología Agropecuaria (INTA -Argentina) |
| language | Inglés |
| publishDate | 2019 |
| publishDateRange | 2019 |
| publishDateSort | 2019 |
| publisher | Elsevier |
| publisherStr | Elsevier |
| record_format | dspace |
| spelling | INTA62292019-10-29T14:28:51Z Systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor-lysate vaccine inducing the rejection of a highly aggressive T-cell lymphoma Di Sciullo, Maria Paula Menay, Florencia Cocozza, Federico Gravisaco, María José Waldner, Claudia Inés Mongini, Claudia Lymphoma Immunologic Adjuvants Immunogenetics Vaccines Linfoma Coadyuvantes Inmunológicos Inmunogenética Vacuna T-cell lymphomas include diverse malignancies. They are rare, some have low survival rates and they lack curative therapies. The aim of this work was to assess whether employing the TLR7 agonist imiquimod and the T-cell costimulatory molecule CD40 or the combination of both as adjuvants of a cell lysate vaccine could enhance the antitumor immune response using a murine T-cell lymphoma model. Immunization with LBC-lysate and imiquimod protected almost all vaccinated animals. A specific humoral and a Th1-type cellular immunity were induced in mice that rejected the lymphoma, characterized by an elevated number of CD4 + T-cells and secretion of IFN-γ, locally and systemically. In contrast, CD40 alone or in combination with imiquimod did not improve the protective response obtained with LBC-lysate and imiquimod. Systemic administration of imiquimod proved to have high potential to serve as a vaccine adjuvant for the treatment of T-cell lymphomas and was effective in this immunotherapy model. Instituto de Biotecnología Fil: Di Sciullo, Maria Paula. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Estudios Farmacológicos y Botánicos; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina Fil: Menay, Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Estudios Farmacológicos y Botánicos; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina Fil: Cocozza, Federico. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Estudios Farmacológicos y Botánicos; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina Fil: Gravisaco, María José. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Biotecnología; Argentina Fil: Waldner, Claudia Inés. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Estudios Farmacológicos y Botánicos; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina Fil: Mongini, Claudia. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Estudios Farmacológicos y Botánicos; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina 2019-10-29T14:17:32Z 2019-10-29T14:17:32Z 2019-06 info:ar-repo/semantics/artículo info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion https://www.sciencedirect.com/science/article/pii/S1521661618304212 http://hdl.handle.net/20.500.12123/6229 1521-6616 https://doi.org/10.1016/j.clim.2019.04.013 eng info:eu-repo/semantics/restrictedAccess application/pdf Elsevier Clinical Immunology 203 : 154-161 (Junio 2019) |
| spellingShingle | Lymphoma Immunologic Adjuvants Immunogenetics Vaccines Linfoma Coadyuvantes Inmunológicos Inmunogenética Vacuna Di Sciullo, Maria Paula Menay, Florencia Cocozza, Federico Gravisaco, María José Waldner, Claudia Inés Mongini, Claudia Systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor-lysate vaccine inducing the rejection of a highly aggressive T-cell lymphoma |
| title | Systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor-lysate vaccine inducing the rejection of a highly aggressive T-cell lymphoma |
| title_full | Systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor-lysate vaccine inducing the rejection of a highly aggressive T-cell lymphoma |
| title_fullStr | Systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor-lysate vaccine inducing the rejection of a highly aggressive T-cell lymphoma |
| title_full_unstemmed | Systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor-lysate vaccine inducing the rejection of a highly aggressive T-cell lymphoma |
| title_short | Systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor-lysate vaccine inducing the rejection of a highly aggressive T-cell lymphoma |
| title_sort | systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor lysate vaccine inducing the rejection of a highly aggressive t cell lymphoma |
| topic | Lymphoma Immunologic Adjuvants Immunogenetics Vaccines Linfoma Coadyuvantes Inmunológicos Inmunogenética Vacuna |
| url | https://www.sciencedirect.com/science/article/pii/S1521661618304212 http://hdl.handle.net/20.500.12123/6229 https://doi.org/10.1016/j.clim.2019.04.013 |
| work_keys_str_mv | AT disciullomariapaula systemicadministrationofimiquimodasanadjuvantimprovesimmunogenicityofatumorlysatevaccineinducingtherejectionofahighlyaggressivetcelllymphoma AT menayflorencia systemicadministrationofimiquimodasanadjuvantimprovesimmunogenicityofatumorlysatevaccineinducingtherejectionofahighlyaggressivetcelllymphoma AT cocozzafederico systemicadministrationofimiquimodasanadjuvantimprovesimmunogenicityofatumorlysatevaccineinducingtherejectionofahighlyaggressivetcelllymphoma AT gravisacomariajose systemicadministrationofimiquimodasanadjuvantimprovesimmunogenicityofatumorlysatevaccineinducingtherejectionofahighlyaggressivetcelllymphoma AT waldnerclaudiaines systemicadministrationofimiquimodasanadjuvantimprovesimmunogenicityofatumorlysatevaccineinducingtherejectionofahighlyaggressivetcelllymphoma AT monginiclaudia systemicadministrationofimiquimodasanadjuvantimprovesimmunogenicityofatumorlysatevaccineinducingtherejectionofahighlyaggressivetcelllymphoma |